NavDX
Healthcare Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
21 Hickory Dr Ste 600, Waltham, Massachu...Phone Number
(833) 628-3747Website
www.navdx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About NavDX
NavDx is an innovative blood test that helps physicians personalize care in HPV-positive cancers, such as head and neck (mouth or throat) or anal cancer. Routine testing with NavDx to track changes in your TTMV Score offers your physician a more complete picture of your cancer status than imaging scans alone. With a simple blood draw, NavDx can detect the presence of human papillomavirus (HPV)-positive cancer anywhere in your body, helping your physician create the best treatment plan for you.Explore more
NavDX Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NavDX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once NavDX has new funding data
Check out if NavDX is spiking on competitors!
NavDX, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if NavDX had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on NavDX recently announced quarterly report
Product Launch: Get notified when NavDX launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at NavDX
Check if NavDX has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to NavDX
Compare insights from companies similar to NavDX, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NavDX is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
NavDX is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about NavDX.
NavDX Tech Stack
A closer look at the technologies used by NavDX
NavDX News & Media
Naveris Announces Expanded Commercial Payor Coverage for NavDx® Test from Blue Shield of California
WALTHAM, Mass.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced that Blue Shield of California, an independent licensee of the Blue Cross Blue Shield Association, provides coverage as of July 1, 2024 for the NavDx® test, Naveris’ proprietary flagship blood test for Tumor Tissue Modified Viral (TTMV®)-HPV DNA. NavDx is the first and only clinically validated circulating TTMV-HPV DNA blood test. It provides a non-invasive andNaveris to Showcase Advances in Precision Surveillance for HPV-Associated Oropharyngeal Cancer Using the NavDx® Test at the 2024 ASTRO Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the presentation of new data at the 66th Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place September 29 – October 2, 2024, in Washington, D.C.. These presentations will showcase the role of the NavDx® test, the first and only clinically validated circulating Tumor Tissue Modified Viral (TTMV®)-HPV DNA blood test, in the managemNaveris Presents New Data on the NavDx® test for HPV-Associated Oropharyngeal Cancer at the 2024 AAO-HNS Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)-- #AAO2024--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the presentation of new data at the 2024 Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), taking place September 28 – October 1, 2024 in Miami Beach, Florida. These presentations highlight the continued innovation of the NavDx®test , the first and only clinically validated circulating Tumor Tissue Modified ViraNew Multicenter Study Highlights Use of the NavDx® Test in Resolving Clinically Indeterminate Findings
WALTHAM, Mass.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, in collaboration with eight prominent U.S. institutions, announces the publication of a significant study, "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance", in Oral Oncology. The study highlights the crucial role of Naveris' flagship product, the NavDx test, in enhancing diagnostic precision and clinical decision-making in
Read more news
Top Healthcare Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NavDX
Sign Up For FreeTo access detailed company insights
NavDx is an innovative blood test that helps physicians personalize care in HPV-positive cancers, such as head and neck (mouth or throat) or anal cancer. Routine testing with NavDx to track changes in your TTMV Score offers your physician a more complete picture of your cancer status than imaging scans alone. With a simple blood draw, NavDx can det... Read More
